Business model

Biohit, founded in 1988, is a Finnish health technology company focusing on diagnostic products and diagnostic analysis systems for the gastrointestinal tract, as well as health-promoting products. Biohit's product portfolio currently consists of about 10 diagnostic tests, two products that bind acetaldehyde, and monoclonal antibodies for research use. The company's main product segments are products for gastrointestinal tract diagnostics and products that bind and eliminate carcinogenic acetaldehyde.

Our products

GastroPanel® health test

GastroPanel® is a primary examination from a blood sample for those suffering from upper abdominal problems and reflux symptoms. GastroPanel ® used for early detection of gastrointestinal diseases is a set of four tests that evaluate the health of the gastric lining from a blood sample. The test is primarily used as a screening tool to identify patients in need of further treatment and refer them for treatment.

The test set is intended to diagnose Helicobacter infection and an acid-free stomach (atrophic gastritis) and to assess the risk of gastric cancer and duodenal ulcer. The GastroPanel test is used to determine the levels of type I and II pepsinogens, gastrin-17, and antibody levels for Helicobacter pylori found in the blood.

Acetium® products

Biohit has developed and commercialized two Acetium® products that bind acetaldehyde, i.e., a molecule that predisposes to cancer, to reduce its harmful effects in the gastrointestinal tract and in the mouth caused by tobacco smoke.

The Acetium capsule can be used to bind acetaldehyde in the stomach, thus, reducing the risk of cancer.

The Acetium® lozenge for smoking cessation is a nicotine-free natural product containing L-cysteine which binds about 90% of acetaldehyde released into saliva from tobacco smoke that predisposes smokers to cancer and over time the lozenge reduces the pleasure of smoking.


Biohit's historical development can be divided into the following steps:


  • 1988 the company is founded

  • 1999 Biohit is listed

  • 2001 the GastroPanel® test is introduced for research use

  • 2005 GastroPanel® is introduced to the market

  • 2010 launch of the Acetium® capsule


  • 2013 joint venture in Italy and China, Biohit Healthcare (Hefei) Co. Ltd.

  • 2016 production of GastroPanel® products begins in China

  • 2017 sales of the Acetium® lozenge to help quit smoking begins

  • 2018 Biohit Healthcare (Hefei) buys a 33% share of Biohit


  • 2020 the effects of the pandemic decrease Biohit's net sales as the focus of the diagnostic market shifts heavily to COVID testing

  • 2021 GastroPanel® quick test from venous blood is launched

  • 2022 GastroPanel® quick test from fingerprick blood samples is launched

  • 2021–2023 strategy focuses on strengthening business fundamentals

Global distribution network

Our products are sold through our subsidiaries (UK and Italy) and our global distribution network. With the exception of subsidiaries, Biohit has no own direct sales, but we have built a committed and concentrated network of distributors and partners, whose scope and effectiveness have been actively developed and new potential distributors are carefully screened. Making the distribution chain more efficient has been a strategic priority for the company for a few years.

Distribution agreements for diagnostic products are especially being signed with distributors specialized in gastroenterology, i.e., stomach diseases. Own partners have also been sought for Acetium® products, with whom greater cooperation is aimed for, such as regional clinical trials.

Product development is key

Biohit's operations are based on innovative product development. The company aims to develop and expand the range of diagnostic tests and health-promoting products through continued R&D investments. R&D focuses on developing new products and updating the life cycle of existing products, as well as improving the usability of products. We mainly develop diagnostic tests ourselves, in addition to which we use external experts and subcontractors to assist in R&D activities.

Outlook and guidance

See our outlook and guidance for 2023


Read analyst estimates